SECONDARY PREVENTION OF ISCHEMIC STROKE IN PATIENTS WITH TYPE 2 DIABETES MELITUS


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Inadequate glycemic control and a higher risk for hypoglycemic states during therapy are among the reasons for a 6-fold increase in the incidence rate of stroke in patients with type 2 diabetes mellitus (DM2). Sitagliptin is a current dipeptidyl peptidase-4 inhibitor, a glucose-lowering agent that promotes the prevention of macro- and microvascular complications in patients with DM2.

Full Text

Restricted Access

About the authors

V. Shlshkova

Center for Speech Pathology and Neurorehabilitation

Email: veronika-1306@mail.ru
Candidate of Medical Sciences Moscow

A. Remennik

Center for Speech Pathology and Neurorehabilitation

Candidate of Medical Sciences Moscow

V. Shklovsky

Center for Speech Pathology and Neurorehabilitation

Professor Academician of the Russian Academy of Sciences Moscow

Yu. Fukalov

Center for Speech Pathology and Neurorehabilitation

Moscow

References

  1. Дамулин И.В., Парфенов В.А., Скоромец А.А. и др. Нарушения кровообращения в головном и спинном мозге. В кн.: Болезни нервной системы. Руководство для врачей. Под ред. Н.Н. Яхно / М.: Медицина, 2005; 1: 231302.
  2. Инсульт: диагностика, лечение и профилактика. Под ред. З.А. Суслиной, М.А. Пирадова / М.: МЕДпресс-информ, 2008; 288 с.
  3. Фейгин В., Виберс Д., Браун Р. Инсульт. Клиническое руководство / М.: Бином. - СПб.: Диалект, 2005.
  4. Dhamoon M., Tai W., Boden-Albala B. et al. Risk of myocardial infarction or vascular death after first ischemic stroke // Stroke. - 2007; 38: 1752-8.
  5. Furie K., Kasner S., Adams R. et al. Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack. AHA/ASA Guideline // Stroke. - 2011; 42: 227-76.
  6. Rydén L. et al. Guidelines on diabetes, pre-diabetes and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Disease of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD) // Eur. Heart J. - 2007; 28: 88-136.
  7. Bloomgarden Z. Cardiovascular disease in diabetes // Diabetes Care. - 2008; 31: 1260-7.
  8. Furie K., Kasner S., Adams R. et al. Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack. AHA/ASA Guideline // Stroke. - 2011; 42: 227-76.
  9. Censori B. еt al. Dementiaafter first stroke // Stroke. - 1996; 27: 1205-10.
  10. Gaede P., Vedel P., Larsen N. et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes // N. Engl. J. Med. - 2003; 348: 383-93.
  11. Mancia G: Optimal control of blood pressure in patients with diabetes reduces the incidence of macro- and microvascular events // J. Hypertens. - 2007; 25 (Suppl. 1): S7-12.
  12. Kausik K. еt al. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials // Lancet. - 2009; 373 (9677): 1765-72.
  13. Turner R., Cull C., Frighi V. et al. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: Progressive requirement for multiple therapies (ukpds 49). Uk prospective diabetes study (ukpds) group // JAMA. - 1999; 281: 2005-12.
  14. Dormandy J., Charbonnel, Eckland D. et al. PROactive Investigators. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive study (PROspectivepioglit Azone Clinical Trial In macro Vascular Events): randomized controlled trial // Lancet. - 2005; 366: 1279-89.
  15. Ban K., Hoefer J., Bolz S. et al. Mechanisms underlying cardioprotective effects of glucagons-life peptide-1 in ischemia-reperfusion ingury // Can. Сardiovascular. Congress. Quebec City. October 20-24, 2007.
  16. Nystrom T., Gutniac M. Zhang Q. et al. Effects of glucagons-like peptide-1 on endotelial function in type 2 diabetes patients with stable coronary artery disease // Am. J. Phisiol. Endocrinil. Metаb. - 2004; 287: 1289-95.
  17. Zaruba M. еt al. Synergy between CD26/DPP-IV inhibition and G-CSF improves cardiac function after acute myocardial infarction // Cell. Stem. Cell. -2009; 4 (4): 313-2.
  18. Read P., Khan F. DPP-4 inhibition by sitagliptin improves the myocardial response to dobutamine stress and mitigates stunning in a pilot study of patients with coronary artery disease // Circ. Cardiovasc. Imaging. - 2010; 3 (2): 195-201.
  19. Ye Y., Keyes K. The myocardial infarct size-limiting effect of sitagliptin is PKA-dependent, whereas the protective effect of pioglitazone is partially dependent on PKA // Am. J. Physiol. Heart. Circ. Physiol. - 2010; 298 (5): 1454-65.
  20. Gomez N., Touihri K. Dipeptidyl peptidase IV inhibition improves cardiorenal function in overpacing-induced heart failure // Eur. J. Heart Fail. - 2012; 14 (1): 14-21.
  21. Theiss H., Brenner C. Safety and efficacy of SIT Agliptin plus GRanulocyte-colony-stimulating factor in patients suffering from Acute Myocardial Infarction (SITAGRAMI-Trial)-rationale, design and first interim analysis // Int. J. Cardiol. -2010; 145 (2): 282-4.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2012 Russkiy Vrach Publishing House

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies